Table 1.
Summary of clinical efficacy scores from trials evaluating abatacept
| ACR20 (%) | ACR50 (%) | ACR70 (%) | DAS28 LDAS (%) | DAS28 remission (%) | |||||||||||
| Trial authors | Study phase | Study cohort | n | Duration | Background therapy | A | P | A | P | A | P | A | P | A | P |
| Moreland et al. [19] | II | DMARD failure | 214 | 3 months | None | 53% | 31% | ||||||||
| Kremer et al. [20] | II | MTX failure | 339 | 6 months | MTX | 60% | 35.3% | 36.5% | 11.8% | 16.5% | 1.7% | ||||
| Kremer et al. [21] | II | MTX failure | 339 | 1 year | MTX | 62.6% | 36.1% | 41.7% | 20.2% | 20.9% | 7.6% | 49.6% | 21.9% | 34.8% | 10.1% |
| Kremer et al. [22] | III (AIM) | MTX failure | 652 | 1 year | MTX | 73.1% | 39.7% | 48.3% | 18.2% | 28.8% | 6.1% | 42.5% | 9.9% | 23.8% | 1.9% |
| Genovese et al. [29] | III (ATTAIN) | TNF-α antagonist Failure | 391 | 6 months | MTX, other DMARD | 50.4% | 19.5% | 20.3% | 3.8% | 10.2% | 1.5% | 17.1% | 3.1% | 10% | 0.8% |
| Schiff et al. [28] | III (ATTEST) | MTX failure: abatacept (A) or infliximab (I) active arms | 431 | 6 months | MTX | A: 66.7% | 41.8% | A: 40.4% | 20% | A: 20.5% | 9.1% | A: 20.7% | 10.8% | A: 11.3% | 2.9% |
| I: 59.4% | I: 37% | I: 24.2% | I: 25.6% | I: 12.8% | |||||||||||
| 1 year | MTX | A: 72.4% | A: 45.5% | A: 26.3% | A: 35.3% | A: 18.7% | |||||||||
| I: 55.8% | I: 36.4% | I: 20.6% | I: 22.4% | I: 12.2% | |||||||||||
For abatacept (A), only responses for 10 mg/kg are included. ACR20/50/70, at least 20%/50%/70% improvement in the American College of Rheumatology criteria for rheumatoid arthritis; AIM, Abatacept in Inadequate responders to Methotrexate; ATTAIN, Abatacept Trial in Treatment of Anti-TNF INadequate responders; ATTEST, Abatacept or infliximab versus placebo, a Trial for Tolerability, Efficacy and Safety in Treating RA; DAS28, Disease Activity Score using 28 joint counts; DMARD, disease-modifying antirheumatic drug; LDAS, low disease activity scores; LTE, long-term extension; MTX, methotrexate; P, placebo; TNF, tumor necrosis factor.